Health
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants – PharmiWeb.com
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase…
- The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
- Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or…
Continue Reading
-
Noosa News19 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News18 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General22 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General13 hours ago‘Potential’ hacker contacts Qantas over data breach